Aurélie Thuleau

511 total citations
15 papers, 378 citations indexed

About

Aurélie Thuleau is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Aurélie Thuleau has authored 15 papers receiving a total of 378 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 4 papers in Immunology. Recurrent topics in Aurélie Thuleau's work include Cancer Cells and Metastasis (4 papers), Immunotherapy and Immune Responses (3 papers) and Advanced Chemical Sensor Technologies (3 papers). Aurélie Thuleau is often cited by papers focused on Cancer Cells and Metastasis (4 papers), Immunotherapy and Immune Responses (3 papers) and Advanced Chemical Sensor Technologies (3 papers). Aurélie Thuleau collaborates with scholars based in France, Italy and Germany. Aurélie Thuleau's co-authors include Elisabetta Marangoni, Ivan Bièche, Anne Vincent‐Salomon, Didier Decaudin, Philémon Sirven, Sylvain Lefort, Fatima Mechta‐Grigoriou, Yann Kieffer, Jean‐Jacques Fontaine and Sophie Château‐Joubert and has published in prestigious journals such as PLoS ONE, Cancer Research and Oncogene.

In The Last Decade

Aurélie Thuleau

15 papers receiving 375 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aurélie Thuleau France 10 180 179 108 101 61 15 378
Francis G Gabriel United Kingdom 9 165 0.9× 142 0.8× 77 0.7× 99 1.0× 49 0.8× 11 358
Bridget Finnerty United States 6 169 0.9× 212 1.2× 78 0.7× 41 0.4× 24 0.4× 7 379
Alexander Schulz Germany 9 181 1.0× 257 1.4× 98 0.9× 51 0.5× 49 0.8× 13 419
Ashleigh Stewart Australia 6 278 1.5× 209 1.2× 44 0.4× 206 2.0× 34 0.6× 15 425
Marni B. Siegel United States 11 160 0.9× 182 1.0× 156 1.4× 44 0.4× 76 1.2× 16 410
Martin Udart Germany 10 214 1.2× 248 1.4× 47 0.4× 42 0.4× 36 0.6× 15 428
Judith Kohlmeyer Germany 7 439 2.4× 332 1.9× 82 0.8× 374 3.7× 55 0.9× 7 737
Farhad Dastmalchi United States 13 169 0.9× 191 1.1× 93 0.9× 216 2.1× 65 1.1× 22 551
Roman Hennel Germany 12 169 0.9× 171 1.0× 52 0.5× 145 1.4× 70 1.1× 13 433
Richard Yu United States 4 177 1.0× 237 1.3× 95 0.9× 86 0.9× 31 0.5× 6 365

Countries citing papers authored by Aurélie Thuleau

Since Specialization
Citations

This map shows the geographic impact of Aurélie Thuleau's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aurélie Thuleau with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aurélie Thuleau more than expected).

Fields of papers citing papers by Aurélie Thuleau

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aurélie Thuleau. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aurélie Thuleau. The network helps show where Aurélie Thuleau may publish in the future.

Co-authorship network of co-authors of Aurélie Thuleau

This figure shows the co-authorship network connecting the top 25 collaborators of Aurélie Thuleau. A scholar is included among the top collaborators of Aurélie Thuleau based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aurélie Thuleau. Aurélie Thuleau is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Leemans, Michelle, Pierre Bauër, Aurélie Thuleau, et al.. (2023). Screening of Breast Cancer from Sweat Samples Analyzed by 2-Dimensional Gas Chromatography-Mass Spectrometry: A Preliminary Study. Cancers. 15(11). 2939–2939. 8 indexed citations
2.
Thuleau, Aurélie, Caroline Gilbert, Pierre Bauër, et al.. (2018). A New Transcutaneous Method for Breast Cancer Detection with Dogs. Oncology. 96(2). 110–113. 14 indexed citations
3.
Thuleau, Aurélie, José Dugay, Catherine Dacremont, et al.. (2018). Volatile Organic Compounds of Malignant Breast Cancer Wounds: Identification and Odors.. PubMed. 30(11). 337–344–337–344. 10 indexed citations
4.
Massonnet, Gérald, David Gentien, Zofia Maciorowski, et al.. (2016). Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization. PLoS ONE. 11(7). e0157670–e0157670. 9 indexed citations
5.
Lefort, Sylvain, Aurélie Thuleau, Yann Kieffer, et al.. (2016). CXCR4 inhibitors could benefit to HER2 but not to triple-negative breast cancer patients. Oncogene. 36(9). 1211–1222. 68 indexed citations
6.
Ribas, Ricardo, Sunil Pancholi, Stephanie K. Guest, et al.. (2015). AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. Molecular Cancer Therapeutics. 14(9). 2035–2048. 49 indexed citations
7.
Legrier, Marie‐Emmanuelle, Ivan Bièche, Olivier Déas, et al.. (2015). Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer. British Journal of Cancer. 114(2). 177–187. 64 indexed citations
8.
Cottu, Paul, Ivan Bièche, Franck Assayag, et al.. (2014). Acquired Resistance to Endocrine Treatments Is Associated with Tumor-Specific Molecular Changes in Patient-Derived Luminal Breast Cancer Xenografts. Clinical Cancer Research. 20(16). 4314–4325. 42 indexed citations
9.
Plater, Ludmilla de, Anne Vincent‐Salomon, Frédérique Berger, et al.. (2014). Predictive Gene Signature of Response to the Anti-TweakR mAb PDL192 in Patient-Derived Breast Cancer Xenografts. PLoS ONE. 9(11). e104227–e104227. 11 indexed citations
10.
Maciorowski, Zofia, Jawida Touhami, Aurélie Thuleau, et al.. (2013). Optimization of tumor xenograft dissociation for the profiling of cell surface markers and nutrient transporters. Laboratory Investigation. 93(5). 611–621. 32 indexed citations
11.
Pouzoulet, Frédéric, Franck Assayag, Frédérique Mégnin-Chanet, et al.. (2013). Abstract 4428: Pre-clinical studies of the therpaeutic effect of a PARP inhibitor combined with radiotherapy for breast cancer treatment.. Cancer Research. 73(8_Supplement). 4428–4428. 1 indexed citations
12.
Cottu, Paul, Jean‐Jacques Fontaine, Franck Assayag, et al.. (2013). Abstract 85: Endocrine resistant luminal breast cancer xenografts are powerful models for the analysis of sensitivity to endocrine and everolimus treatments .. Cancer Research. 73(8_Supplement). 85–85. 1 indexed citations
13.
Madic, Jordan, Sophie Piperno‐Neumann, Vincent Servois, et al.. (2012). Pyrophosphorolysis-Activated Polymerization Detects Circulating Tumor DNA in Metastatic Uveal Melanoma. Clinical Cancer Research. 18(14). 3934–3941. 65 indexed citations
14.
Gentien, David, Stéphane Depil, Pierre Gestraud, et al.. (2012). Abstract 3000: Molecular profiling of residual tumor cells after various chemotherapies shows distinct gene expression patterns in patient-derived breast cancer xenografts. Cancer Research. 72(8_Supplement). 3000–3000. 3 indexed citations
15.
Cassoux, Nathalie, Franck Assayag, Fariba Némati, et al.. (2012). Intraocular Treatments of a New Orthotopic Primary Human Retinoblastoma Xenograft. 53(14). 6869–6869. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026